Xencor, Inc. (XNCR) Receives Average Rating of “Hold” from Brokerages
Shares of Xencor, Inc. (NASDAQ:XNCR) have earned an average recommendation of “Hold” from the nine research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $28.00.
Several equities research analysts recently weighed in on the company. Canaccord Genuity reissued a “buy” rating and set a $36.00 price objective on shares of Xencor in a report on Tuesday, August 8th. BidaskClub downgraded Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine raised Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research downgraded Xencor from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, Wedbush reissued an “outperform” rating and set a $29.00 price objective on shares of Xencor in a report on Friday, June 16th.
Xencor (NASDAQ XNCR) traded down 0.16% during trading on Friday, reaching $24.79. The company’s stock had a trading volume of 249,273 shares. The stock’s market cap is $1.16 billion. The company’s 50 day moving average price is $22.05 and its 200-day moving average price is $22.47. Xencor has a 1-year low of $18.45 and a 1-year high of $29.38.
Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%. The company had revenue of $13.34 million for the quarter, compared to analyst estimates of $8.15 million. Equities analysts forecast that Xencor will post ($1.17) earnings per share for the current fiscal year.
In other Xencor news, major shareholder John S. Stafford III acquired 25,000 shares of the stock in a transaction dated Wednesday, August 16th. The stock was purchased at an average cost of $20.96 per share, with a total value of $524,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder John S. Stafford III acquired 27,000 shares of the stock in a transaction dated Friday, August 11th. The stock was acquired at an average cost of $21.13 per share, with a total value of $570,510.00. The disclosure for this purchase can be found here. Over the last three months, insiders bought 215,551 shares of company stock valued at $4,386,916. Corporate insiders own 4.03% of the company’s stock.
Several hedge funds have recently bought and sold shares of XNCR. Bank of New York Mellon Corp raised its position in shares of Xencor by 15.8% in the 1st quarter. Bank of New York Mellon Corp now owns 198,988 shares of the biopharmaceutical company’s stock worth $4,759,000 after acquiring an additional 27,109 shares in the last quarter. Parametric Portfolio Associates LLC increased its position in Xencor by 0.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 36,253 shares of the biopharmaceutical company’s stock valued at $867,000 after buying an additional 209 shares in the last quarter. Prudential Financial Inc. bought a new stake in Xencor in the 1st quarter valued at about $600,000. Clinton Group Inc. increased its position in Xencor by 4.6% in the 1st quarter. Clinton Group Inc. now owns 15,987 shares of the biopharmaceutical company’s stock valued at $382,000 after buying an additional 700 shares in the last quarter. Finally, Victory Capital Management Inc. increased its position in Xencor by 2,826.5% in the 1st quarter. Victory Capital Management Inc. now owns 28,533 shares of the biopharmaceutical company’s stock valued at $682,000 after buying an additional 27,558 shares in the last quarter. 76.92% of the stock is owned by hedge funds and other institutional investors.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.